<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04184908</url>
  </required_header>
  <id_info>
    <org_study_id>UNIVERSITY</org_study_id>
    <nct_id>NCT04184908</nct_id>
  </id_info>
  <brief_title>Clinical Study New Gel for Xerostomia</brief_title>
  <acronym>XEROSTOMIA</acronym>
  <official_title>Clinical Study to Evaluate the Efectiveness and Tolerability of a New Gel for Xerostomia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Universidad de Murcia</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Universidad de Murcia</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      At present, there is no single consensus protocol for the treatment of oral dryness, although
      the main objective is to improve the quality of life of patients. Current therapy for the
      control of xerostomia is based on the following measures:

        1. General measures ; review and control of drugs,hydration and dietary advice:

           The main recommendations are found in the following scheme.

        2. Saliva stimulants( Topics and sistemic )The option of using chewing stimuli by chewing
           gum with non-cariogenic sweeteners helps to improve symptoms. The investigators can also
           use gustatory stimuli, such as citric acid that is a potent stimulator of salivary
           secretion.

           Among the most commonly used pharmacological agents are: pilocarpine, bethanecol,
           civemiline

        3. Saliva substitutes or artificial saliva. Saliva substitutes can provide a moisture
           retention layer in the oral mucosa and can be administered by liquids, spray, pills or
           gels. Topical treatments have few adverse effects and improve the quality of life of
           patients with xerostomia; In addition, they maintain oral health.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Randomized, double-blind, placebo-controlled clinical study to evaluate the efficacy and
      tolerability in patients with a non-commercialized gel and property of the promoter to treat
      xerostomia.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 1, 2019</start_date>
  <completion_date type="Anticipated">December 31, 2020</completion_date>
  <primary_completion_date type="Actual">November 2, 2019</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>OHIP 14</measure>
    <time_frame>1moth</time_frame>
    <description>Quality of oral life. minimun 0 maximum 56 points. As it gets higher, quality of life decreases</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Sialometry</measure>
    <time_frame>1moth</time_frame>
    <description>Drenaje</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Test Thonsom xerostomy</measure>
    <time_frame>1moth</time_frame>
    <description>Xerostomia Inventory. the higher the outcome, quality of life decreases</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>XEROSTOMIA</condition>
  <arm_group>
    <arm_group_label>GROUP EXPERIMENTAL</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Gel xerostomia Apply 2-3 cm of the gel on the tongue, gums and oral mucosa, at least three times a day, if necessary it can be applied at night</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CONTROL GROUP</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Gel placebo Apply 2-3 cm of the gel on the tongue, gums and oral mucosa, at least three times a day, if necessary it can be applied at night</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>gel xerostomia</intervention_name>
    <description>Apply 2-3 cm of the gel on the tongue, gums and oral mucosa, at least three times a day, if necessary it can be applied at night</description>
    <arm_group_label>GROUP EXPERIMENTAL</arm_group_label>
    <other_name>lubricant and remineralizing agents</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>gel placebo</intervention_name>
    <description>Apply 2-3 cm of the gel on the tongue, gums and oral mucosa, at least three times a day, if necessary it can be applied at night</description>
    <arm_group_label>CONTROL GROUP</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subjects of both sexes 2. Over 18 years. 3. Adequate cultural level and understanding
             of the clinical study. 4. Agree to voluntarily participate in the study and give their
             informed consent in writing 5. Present xerostomia of more than three months of
             evolution / sialometry less than 0.2ml / 5 min.

        Exclusion criteria

        The presence of at least one of the following criteria will be grounds for exclusion from
        the clinical trial:

          1. Presence of health problems that may compromise adherence to the study protocol.

          2. Pregnant or breastfeeding women.

          3. Present hypersensitivity to any component of the product under study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Pia López-Jornet, PhD</last_name>
    <phone>639473308</phone>
    <email>majornet@um.es</email>
  </overall_contact>
  <location>
    <facility>
      <name>Lopez-Jornet Pia</name>
      <address>
        <city>Murcia</city>
        <state>N/A = Not Applicable</state>
        <zip>30008</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lopez-Jornet Pia</last_name>
      <phone>639473308</phone>
      <email>majornet@um.es</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Lopez-Jornet Pia</name>
      <address>
        <city>Murcia</city>
        <state>N/A = Not Applicable</state>
        <zip>30008</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Lopez-Jornet Pia</last_name>
      <phone>639473308</phone>
      <email>majornet@um.es</email>
    </contact>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <reference>
    <citation>Assery MKA. Efficacy of Artificial Salivary Substitutes in Treatment of Xerostomia: A Systematic Review. J Pharm Bioallied Sci. 2019 Feb;11(Suppl 1):S1-S12. doi: 10.4103/jpbs.JPBS_220_18. Review.</citation>
    <PMID>30923424</PMID>
  </reference>
  <reference>
    <citation>Gil-Montoya JA, Silvestre FJ, Barrios R, Silvestre-Rangil J. Treatment of xerostomia and hyposalivation in the elderly: A systematic review. Med Oral Patol Oral Cir Bucal. 2016 May 1;21(3):e355-66. Review.</citation>
    <PMID>27031061</PMID>
  </reference>
  <reference>
    <citation>Łysik D, Niemirowicz-Laskowska K, Bucki R, Tokajuk G, Mystkowska J. Artificial Saliva: Challenges and Future Perspectives for the Treatment of Xerostomia. Int J Mol Sci. 2019 Jun 29;20(13). pii: E3199. doi: 10.3390/ijms20133199. Review.</citation>
    <PMID>31261876</PMID>
  </reference>
  <verification_date>December 2019</verification_date>
  <study_first_submitted>November 29, 2019</study_first_submitted>
  <study_first_submitted_qc>December 3, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">December 4, 2019</study_first_posted>
  <last_update_submitted>December 3, 2019</last_update_submitted>
  <last_update_submitted_qc>December 3, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">December 5, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Universidad de Murcia</investigator_affiliation>
    <investigator_full_name>Pia Lopez Jornet</investigator_full_name>
    <investigator_title>UNIVERSIDAD DE MURCIA</investigator_title>
  </responsible_party>
  <keyword>dry mouth</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Xerostomia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

